$ANIX (2 of 2) B Riley...ANIX's chimeric antigen receptor T cell (CAR-T cell) like program, dubbed "chimeric endocrine receptor T cell" (CER-T cell) is on track to file its IND during C1Q21. We continue to believe moving into human trials will be a significant catalyst for ANIX and will materially increase the company's intrinsic value. Thus, we maintain our Buy rating and $9 price target.
  • 6